sandoz semaglutide CEO forecasts a Q1 or Q2 market entry for biosimilars in Canada Rybelsus is from the class of medicines called GLP Health Canada approval backlog expected

Metformin Pros: Generally well-tolerated, low cost, potential cardiovascular benefits

In the largest clinical study, participants lost an average of almost 15% of their initial body weight after taking semaglutide GLP-1

Clinical note: Dose selection and titration are determined by your provider based on your response, goals, and clinical tolerance

"This medication is designed to reduce hunger and help you feel satisfied after smaller meals

Gastrointestinal Adverse Reactions In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients who received RYBELSUS than placebo: RYBELSUS 14 mg once daily (41%), RYBELSUS 7 mg once daily (32%) and placebo (21%), including severe reactions (RYBELSUS 14 mg 2.0%, RYBELSUS 7 mg 0.6%, placebo 0.3%)